RxDoctor Payments Data

Sujata Prasad, MD

Internal Medicine · Hartford, CTNPI 1366444671

Payments from drug & device makers

$15,929in general payments, 2019–2025

Across 420 payments — averaging $37.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Novo Nordisk$2K
  • AbbVie$1K
  • Merck$1K
  • EMD Serono, Inc.$983
  • GSK$965
  • plus $6K from 35 others

What the payments were for

  • Food & beverage$15,905100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,929 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$26,697
Medicare patients
52
Services billed
349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol72$101,167
RybelsusSemaglutide44$62,722
JanuviaSitagliptin Phosphate15$25,050
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$18,586
JardianceEmpagliflozin11$12,514
Atorvastatin Calcium230$2,033
Losartan Potassium134$1,019
Amlodipine Besylate183$986
Levothyroxine Sodium110$968
Rosuvastatin Calcium65$920
Methenamine Hippurate13$835
Metoprolol Succinate62$662
Lisinopril93$557
Duloxetine Hcl18$545
Famotidine45$540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$3,205$101,16772 claims
Novo NordiskRybelsus$2,072$62,72244 claims
MerckJanuvia$1,229$25,05015 claims
GSKTrelegy Ellipta$965$18,58623 claims
Boehringer IngelheimJardiance$563$12,51411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →